miR-217 inhibits laryngeal cancer metastasis by repressing AEG-1 and PD-L1 expression
Metrics: HTML 1212 views | ?
Susheng Miao1,*, Xionghui Mao1,*, Shu Zhao3, Kaibin Song1, Cheng Xiang1, Yuanjing Lv1, Huanyv Jiang1, Lei Wang1, Baojun Li1, Xianguang Yang1, Zhennan Yuan1, Cheng Xiu1, Hongxue Meng2 and Ji Sun1
1Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, China
2Department of Pathology, Harbin Medical University Cancer Hospital, Harbin 150081, China
3Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China
*These authors have contributed equally to the work
Hongxue Meng, email: email@example.com
Ji Sun, email: firstname.lastname@example.org
Keywords: laryngeal cancer, metastasis, mir-217, AEG-1, PD-L1
Received: September 26, 2016 Accepted: April 14, 2017 Published: July 10, 2017
High incidences of laryngeal cancer have been reported recently. Increasing our understanding of the molecular mechanisms underlying this malignancy could reveal more effective approaches to treating laryngeal cancer patients and so improve their prognoses. In this study, we explored the biological effects of miR-217 on laryngeal cancer. miR-217 potently inhibited multiple metastatic traits, including cell migration, invasion, proliferation, apoptosis, and EMT, as well as angiogensis. These effects were achieved through downregulation of the miR-217 target gene, AEG-1 and PD-L1. Clinical expression and animal model studies further confirmed our results. These findings provide new insight into the physiological effects of miR-217 in laryngeal cancer and its potential therapeutic use.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.